HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

VMV Hypoallergenics not sensitive to recession

This article was originally published in The Rose Sheet

Executive Summary

Company that has devised a proprietary "VH" rating system for hypoallergenicity - like the SPF system for sunscreens, it says - saw its online sales grow by 180% in 2008, compared with the prior year. At the same time the firm is expanding its retail presence; while previously available to U.S. consumers only at 1www.vmvhypoallergenics.com, the company's products now are sold through C.O. Bigelow, Bliss Catalog, Clyde's New York and Henri Bendel's, and soon will be offered by Fred Segal, according to a spokesperson. Most VMV skin-care and makeup items are "VH 27," meaning they contain none of the 27 allergens compiled by the North American Contact Dermatitis Group. The firm says it conducts patch tests for all its products, as well as every raw material used, and supports its claims with clinical research. This May, VMV will add Armada Post Procedure SPF 50 and Armada Sun Care for Baby SPF 50 to its sun-protection portfolio, the company says

You may also be interested in...



Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015927

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel